Full Title
A Single-Arm, Open-Label, Multi-Center, Phase 1b/ 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (TLBL) (TENACITY-01)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Mark Geyer’s office at 646-608-3745.
Protocol
25-380
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT07070219